3078 Hits
3078 Hits
WP IP
News and commentary on IP issues
Not all Unitary Patents are created equal
Different Unitary Patents can have different geographical coverage. The Unitary Patent states are fixed when a Unitary Patent is registered during the grant stage of a European patent. Countries that subsequently become Unitary Patent state...
3576 Hits
3576 Hits
3072 Hits
3072 Hits
2645 Hits
2645 Hits
3717 Hits
3717 Hits
3964 Hits
3964 Hits
3366 Hits
3366 Hits
3887 Hits
3887 Hits
3406 Hits
3406 Hits
As of 1 January 2021, a UK, Gibraltar or Channel Islands address for service will be required for any new UK IP rights. This change has received parliamentary approval and is implemented in a UK IPO notice (TPN 2/2020) dated 21 December 2020. Action should be taken and we would be very happy to assist. If your IP rights are&nbs...
4305 Hits
4305 Hits
We are delighted that the UK Court of Appeal has today granted Dr Thaler the right to appeal the DABUS decision, which involves the important issue of patentability of inventions created by AI systems. Williams Powell is handling the DABUS patent applications as well as the UK and EPO appeals. The cases had been rejected by the UK High Court. The o...
3532 Hits
3532 Hits
As of January 2021, parties will no longer have free choice on whether a hearing (oral proceedings) during examination or opposition is in person or via video conferencing before the European Patent Office (EPO). Video conferences will be the default. 12 months ago, we would have had to fight for a hearing (oral proceedings) to be held with t...
3489 Hits
3489 Hits
In the EU, a designer is able to benefit from both unregistered and registered design rights. Although cheap and easy to obtain, many designers have chosen to rely on registered designs only for the more important designs/products and fall back on unregistered rights for the rest. However, that may not be possible in certain situations as of 1 Janu...
2722 Hits
2722 Hits
A Supplementary Protection Certificate (SPC) can provide up to five years additional protection for a patented active ingredient of a pharmaceutical product that has received a marketing authorisation. The objective is to compensate a patent holder for the delay in being able to use the patent by the need to obtain the marketing authorisation. An S...
2364 Hits
2364 Hits
We have previously written about our involvement in filing and prosecuting patent applications for two inventions created by the AI inventor DABUS, and naming DABUS (the true deviser of the inventions) as the inventor.The UK IPO found the inventions to be both novel and inventive, and therefore, in principle, protectable by patent. ...
2739 Hits
2739 Hits
On 20 July 2020, the UK Government announced its official withdrawal from the Unified Patent Court (UPC) Agreement. This is a disappointment but not unexpected. Does this mark an end to over 40 years of efforts to produce a harmonised IP litigation process in Europe? Of course not. The UPC has, in recent year...
3167 Hits
3167 Hits
Ever since the Decision issued back in 1997 in the case of Biogen v Medeva the concept of insufficiency has been extended, particularly in the chemical and biotech fields, to include claims that have "excessive breadth" (so-called "Biogen insufficiency"). The Courts in the UK have applied this frequently to revoke patents that they decide clai...
3377 Hits
3377 Hits
Regeneron Pharmaceuticals' European patent EP 1360287 and its divisional EP 2264163 relate to methods of producing transgenic mice able to produce antibodies having human sequences, and the mice produced thereby. These patents covered the idea of producing mice having mixed human-murine gene sequences that could be subsequently modified t...
3511 Hits
3511 Hits
The European patent office has announced here that until 31 August 2020, no surcharge is payable for late paid renewal fees. This provision applies to EPO renewal fees having a deadline (without extension) between 15 March 2020 and 30 August 2020. Cases falling into this provision, will be deemed validly paid if the renew...
2919 Hits
2919 Hits
3795 Hits
3795 Hits
By accepting you will be accessing a service provided by a third-party external to https://www.williamspowell.com/
©
2007 - 2024
Williams Powell
All rights reserved.
Williams Powell are regulated by IPREG whose code of conduct can be found here.These pages aim to provide a source of information for both non-professional enquirers e.g. inventors and their companies in the U.K. and professional consultants and advisers throughout the rest of the world. The pages are not intended to provide legal advice, which will only be provided on direct application to us in the formal context of a client/attorney relationship.
The information provided is correct to the best of our knowledge and belief, but is provided without obligation or guarantee. It will be updated from time to time as needed.